Jain Arvind K, Yusuf Helmy, Pattani Aditya, McCarthy Helen O, McDonald Denise M, Kett Vicky L
School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK; Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK.
J Pharm Biomed Anal. 2014 Nov;100:236-242. doi: 10.1016/j.jpba.2014.07.036. Epub 2014 Aug 9.
Gene therapy has the potential to provide safe and targeted therapies for a variety of diseases. A range of intracellular gene delivery vehicles have been proposed for this purpose. Non-viral vectors are a particularly attractive option and among them cationic peptides have emerged as promising candidates. For the pharmaceutical formulation and application to clinical studies it is necessary to quantify the amount of pDNA condensed with the delivery system. There is a severe deficiency in this area, thus far no methods have been reported specifically for pDNA condensed with cationic peptide to form nanoparticles. The current study seeks to address this and describes the evaluation of a range of disruption agents to extract DNA from nanoparticles formed by condensation with cationic fusogenic peptides RALA and KALA. Only proteinase K exhibited efficient and reproducible results and compatibility with the PicoGreen reagent based quantification assay. Thus we report for the first time a simple and reliable method that can quantify the pDNA content in pDNA cationic peptide nanoparticles.
基因治疗有潜力为多种疾病提供安全且有针对性的疗法。为此已提出了一系列细胞内基因递送载体。非病毒载体是一个特别有吸引力的选择,其中阳离子肽已成为有前景的候选者。对于药物制剂以及应用于临床研究而言,有必要对与递送系统凝聚的质粒DNA(pDNA)的量进行定量。这一领域存在严重不足,迄今为止尚未报道专门用于定量与阳离子肽凝聚形成纳米颗粒的pDNA的方法。当前的研究旨在解决这一问题,并描述了一系列用于从与阳离子融合肽RALA和KALA凝聚形成的纳米颗粒中提取DNA的破坏剂的评估。只有蛋白酶K表现出高效且可重复的结果,并且与基于PicoGreen试剂的定量测定法兼容。因此,我们首次报告了一种简单可靠的方法,该方法可以定量pDNA阳离子肽纳米颗粒中的pDNA含量。